SION
Sionna Therapeutics, Inc. Common StockSION
SION
About: Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
–
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$32
169%
upside
Avg. target
$32
169%
upside
High target
$32
169%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Stifel Paul Matteis 6% 1-year accuracy 1 / 16 met price target | 169%upside $32 | Buy Initiated | 4 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025
Neutral
GlobeNewsWire
2 months ago
Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 45th Annual TD Cowen Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET.
Neutral
GlobeNewsWire
2 months ago
Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the closing of its upsized initial public offering of 12,176,467 shares of its common stock at a public offering price of $18.00 per share, which includes 1,588,234 shares issued upon the full exercise by the underwriters of their option to purchase additional shares of common stock in the offering. All of the shares of common stock were sold by Sionna.
Positive
Seeking Alpha
2 months ago
U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO Week
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial Group, and Huachen AI Parking Management Technology. Eight IPOs are currently scheduled to list in the week ahead, although some small issuers may also join the calendar throughout the week.
Neutral
GlobeNewsWire
2 months ago
Sionna Therapeutics Prices Upsized Initial Public Offering
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced the pricing of its upsized initial public offering of 10,588,233 shares of its common stock at a public offering price of $18.00 per share. In addition, Sionna has granted the underwriters a 30-day option to purchase up to 1,588,234 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. Sionna's shares are scheduled to begin trading on the Nasdaq Global Market on February 7, 2025 under the ticker symbol "SION." The offering is expected to close on February 10, 2025, subject to the satisfaction of customary closing conditions. All shares of common stock are being offered by Sionna.
Positive
Seeking Alpha
2 months ago
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK Technology, and TV Channels Network. Two IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.
Positive
Seeking Alpha
3 months ago
Sionna Therapeutics Seeks $100 Million in IPO For Cystic Fibrosis Treatments
Sionna Therapeutics aims to raise $100 million in an IPO to advance its cystic fibrosis drug candidates, currently in Phase 1 and Phase 2 trials. The firm is well-capitalized with $137.5 million in cash and backed by top-tier life science venture capital firms. The cystic fibrosis therapeutics market is projected to grow at a 14.2% CAGR, reaching $22.8 billion by 2030, offering significant market potential.
Charts implemented using Lightweight Charts™